Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals

Oncology Reports

Volumn 7, Issue 3, 2000, Pages 455-466

  Lee, Tom V ^a   Anderson, Brett W ^a   Peoples, George E ^b,d   Castilleja, Agapito ^a   Murray, James L ^a   Gershenson, David M ^a   Ioannides, Constantin G ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

B7; CTL; CTLA 4; HER 2; IL 12; IL 2; Interferon

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; PEPTIDE FRAGMENT;

ARTICLE; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CD8+ T LYMPHOCYTE; CELL CULTURE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; OVARY TUMOR; REFERENCE VALUE;

BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; REFERENCE VALUES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0034186119     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.3.455     Document Type: Article

References (36)

1. Houghton AN: Cancer antigens: immune recognition of self and altered self. J Exp Med 180: 1-4, 1994.
2. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2-individuals. J Exp Med 190: 705-715, 1999.
3. Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, DiNicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V and Parmiani G: An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 190: 651-667, 1999.
4. Marincola FM, Rivoltini L, Salgaller ML, Player M and Rosenberg SA: Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother 19: 266-277, 1996.
5. Goldrath AW and Bevan MJ: Selecting and maintaining a diverse T-cell repertoire. Nature 402: 255-262, 1999.
6. Fisk B, Blevins TL, Wharton JT and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117, 1995.
7. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L and Brugger W: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58: 732-736, 1998.
8. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Macs H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E and Kiessling R: Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163: 1037-1044, 1999.
9. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I and Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432-436, 1995.
10. Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT and Ioannides CG: Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol 5: 743-750, 1998.
11. Babcock B, Anderson BW, Papayannopoulos I, Castilleja A, Murray JL, Stifani S, Kudelka AP, Wharton JT and Ioannides CG: Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino-enhancer of split protein of the Notch complex. Mol Immunol 35: 1121-1133, 1998.
12. Miller C, Ragheb JA and Schwartz RH: Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. J Exp Med 190: 53-64, 1999.
13. Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang C and Reiner SL: Helper T cell differentiation is controlled by the cell cycle. Immunity 9: 229-237, 1998.
14. + T cells become non-responsive (anergic) following activation in the presence of costimulation. J Immunol 163: 102-110, 1999.
15. + memory T cells. J Exp Med 186: 859-865, 1997.
16. Perez VL, Parijs LV, Biuckians A, Zheng XX, Strom TB and Abbas AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6: 411-417, 1997.
17. Sallusto F and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Med Exp 179: 1109-1118, 1994.
18. + peripheral blood monocytes. J Immunol 157: 3850-3859, 1996.
19. Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG and Kudelka AP: Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 17: 45-53, 1997.
20. + T lymphocytes. J Immunol 160: 3642-3647, 1998.
21. Gollob JA, Schnipper CP, Murphy EA, Ritz J and Frank DA: The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 162: 4472-7781, 1999.
22. Gately MK, Renzetti LM, Magram J, Stern A, Adorini L, Gubler U and Presky DH: The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16: 495-521, 1998.
23. Walunas TL, Bakker CY and Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183: 2541-2550, 1996.
24. DeKruyff RH, Gieni RS and Umetsu DT: Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J Immunol 158: 359-366, 1997.
25. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A and Alt FW: Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3: 521-530, 1996.
26. McDyer JF, Goletz TJ, Thomas E, June CH and Seder RA: CD40 ligand/CD40 stimulation regulates the production of IFN-γ from human peripheral blood monuclear cells in an IL-12-and/or CD28-dependent manner. J Immunol 160: 1701-1707, 1998.
27. Yang Y and Wilson JM: CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273: 1862-1864, 1996.
28. Walker W, Aste-Amezaga M, Kastelein RA, Trinchieri G and Hunter CA: IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-γ. J Immunol 162: 5894-5901, 1999.
29. Krummel MF and Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting cells. J Exp Med 183: 2533-2540, 1996.
30. Hemmer B, Stefanova I, Vergelli M, Germain R and Martin R: Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 160: 5807-5814, 1998.
31. Szabo SJ, Dighe AS, Gubler U and Murphy KM: Regulation of the interleukin (IL)-12Rα2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 185: 815-824, 1997.
32. + T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res 58: 5305-5309, 1998.
33. Oehen S and Brduscha-Riem K: Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 161: 5338-5346, 1998.
34. Jacob J and Baltimore D: Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature 399: 593-597, 1999.
35. Guehler SR, Rosalynde JF, Bluestone JA and Barrett TA: Increased threshold for TCR-mediated signaling controls self reactivity of intraepithelial lymphocytes. J Immunol 160: 5341-5346, 1998.
36. Germain RN and Stefanova I: The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 17: 467-522, 1999.